Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered this past year (virtually) to review information presented at ASCO and ESMO 2021, regarding patients dealing with a Lung Cancer diagnosis.

For this series, the doctors discuss new trials for patients with NSCLC and SCLC.  The video discussions cover the following topics:

• IMpower010: Atezolizumab after Chemo in Non-Small Cell Lung Cancer
• Surgical Outcomes and Checkmate 816: Addition of Nivolumab in Early Stage Non-Small Cell Lung Cancer
• FDA Analysis of Immunotherapy With or Without Chemo in Advanced NSCLC and Low PDL-1
• Poseidon Trial: Durvalumab +/- Tremelimumab vs. Chemo Alone
• Carbo/Pemetrexed/Pembro and Acquired Resistance in EGFRm+ or ALK+ NSCLC
• Immune Therapy for Brain Metastases
• CodeBreak 100: Sotorasib in KRAS G12C Mutation
• Amivantamab and Mobocertinib for EGFR Exon 20
• Amivantamab + Lazertinib in EGFR Mutation, Patritumab Deruxtecan in EGFR Mutation-Positive Acquired Resistance
• MYLUNG Consortium: Overall Biomarker Testing
• Lurbinectedin in Small Cell Lung Cancer and the Failed Atlantis Trial
• Circulatory Tumor DNA

To join the conversation, visit https://cancergrace.org/forum.